Baseline characteristics of 22 patients with ET recruited for the randomized study of different aspirin regimens
| Age, y | 51 (29-67) |
| Female sex, n (%) | 13 (59) |
| Time from diagnosis, y | 5 (1-10) |
| Previous vascular events, n | Vein thrombosis (2), ischemic stroke (2) |
| HU, n (%) | 9 (41) |
| JAK-2 mutation, n (%) | 14 (64) |
| Platelet count at diagnosis, × 103/μL | 604 (403-963) |
| BMI at study entry, kg/m2 | 27.5 (25-29) |
| Duration of aspirin therapy, mo | 54 (24-72) |
| Comorbidities, n | Controlled hypercholesterolemia (4); controlled hypertension (3); and controlled hypercholesterolemia and hypertension (1) |
| LDH, units/mL | 380 (371-428) |
| BM fibrosis, n (%) | 3 (14) |
| Age, y | 51 (29-67) |
| Female sex, n (%) | 13 (59) |
| Time from diagnosis, y | 5 (1-10) |
| Previous vascular events, n | Vein thrombosis (2), ischemic stroke (2) |
| HU, n (%) | 9 (41) |
| JAK-2 mutation, n (%) | 14 (64) |
| Platelet count at diagnosis, × 103/μL | 604 (403-963) |
| BMI at study entry, kg/m2 | 27.5 (25-29) |
| Duration of aspirin therapy, mo | 54 (24-72) |
| Comorbidities, n | Controlled hypercholesterolemia (4); controlled hypertension (3); and controlled hypercholesterolemia and hypertension (1) |
| LDH, units/mL | 380 (371-428) |
| BM fibrosis, n (%) | 3 (14) |
Values are medians and IQRs unless otherwise indicated.
BMI indicates body mass index; HU, hydroxyurea; and LDH, lactic dehydrogenase.